Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Resatorvid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 known ✓ | O00206 | 9/20 | 1.00 |
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.43 |
| ▸ | TSPO | P30536 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Resatorvid SCHEMBL29607069 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL1821271 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL872197 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL30113148 | 1.00 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| SCHEMBL871253 | 0.97 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| SCHEMBL871685 | 0.94 | TLR4 (1.00) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944442 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944682 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944518 | 0.90 | TLR4 (0.82) | TLR4MRGPRX1TSPOHRH1KMT2A | |
| Resatorvid SCHEMBL13944446 | 0.90 | TLR4 (0.85) | TLR4MRGPRX1TSPOHRH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197854-B1 | Inhibitors for targeting flaviviruses | NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-10814036-B2 | Drug-eluting live tissue for transplantation | BAYLOR UNIVERSITY (US) | 2020-10-27 | — | — | US | disclosed |
| US-20180177918-A1 | DRUG-ELUTING LIVE TISSUE FOR TRANSPLANTATION | BAYLOR UNIVERSITY | 2018-06-28 | — | — | US | disclosed |
| US-9957287-B2 | Methods and compositions to treat type-1 and type-2 diabetes | CORNELL UNIVERSITY (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170342097-A1 | METHODS AND COMPOSITIONS TO TREAT TYPE-1 AND TYPE-2 DIABETES | CORNELL UNIVERSITY | 2017-11-30 | — | — | US | disclosed |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8901171-B2 | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-26 | — | — | US | disclosed |
| EP-1420783-A1 | STABLE EMULSION COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20030216475-A1 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-20 | — | — | US | disclosed |
| US-20030212114-A1 | Stable emulsion compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1348443-A1 | COMBINATION DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
| EP-1310248-A1 | PHARMACEUTICAL COMPOSITION | Takeda Chemical Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| WO-2003013513-A1 | STABLE EMULSION COMPOSITION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-20 | — | — | WO | disclosed |
| US-6495604-B1 | SUCH AS D-ETHYL-6-(N-(2,4-DIFLUOROPHENYL)SULFAMOYL)-1-CYCLOHEXENE-1-CARBOXYLATE FOR INHIBITING NITRIC OXIDE AND/OR CYTOKINE PRODUCTION; FOR PREVENTING OR TREATING CARDIAC DISEASE, AUTOIMMUNE DISEASE OR SEPTIC SHOCK | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885TSPO 1988/4885 |
| US-11197854-B1 | Inhibitors for targeting flaviviruses | HAVCR2, MME, SPINT2 | TLR4 3526/4885MRGPRX1 1171/4885TSPO 167/4885 |
| US-20170342097-A1 | METHODS AND COMPOSITIONS TO TREAT TYPE-1 AND TYPE-2 DIABETES | IAPP, GPR119, IRS1 | TLR4 13/4885MRGPRX1 1979/4885TSPO 4377/4885 |
| US-20040063685-A1 | Cycloalkene antisepsis drug with antibacterial, antifungal, nonsteroidal antiinflammatory, steroid and/or anticoagulant agents | ELANE, MMP8, SERPINC1 | TLR4 567/4885MRGPRX1 747/4885TSPO 4664/4885 |
| US-20030212114-A1 | Stable emulsion compositions | AHR, NR1H2, NR1H3 | TLR4 2050/4885MRGPRX1 651/4885TSPO 3971/4885 |
| US-20180177918-A1 | DRUG-ELUTING LIVE TISSUE FOR TRANSPLANTATION | CD69, PIGS, FUCA1 | TLR4 2433/4885MRGPRX1 1363/4885TSPO 3423/4885 |
| US-10814036-B2 | Drug-eluting live tissue for transplantation | CD69, PIGS, FUCA1 | TLR4 2433/4885MRGPRX1 1363/4885TSPO 3423/4885 |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885TSPO 1988/4885 |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885TSPO 1988/4885 |
| US-20030216475-A1 | Pharmaceutical composition | ARRB1, ADRA1B, ADRB1 | TLR4 2126/4885MRGPRX1 1041/4885TSPO 4239/4885 |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | TLR4 2222/4885MRGPRX1 1567/4885TSPO 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.